Myriad’s myPath® Melanoma Test Receives Medicare Coverage
Go back to Myriad’s myPath® Melanoma Test Receives Medicare Coverage| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 3.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.22 | 52 Week High | $45.34 | |||
| Open | $3.22 | 52 Week Low | $15.92 | |||
| Day High | $3.22 | P/E | 1.38 | |||
| Day Low | $3.22 | EPS | $2.33 | |||
| Volume | 59 | |||||
